Thursday 16 October, 2025
Objectives: Concomitant treatment with radium-223 and paclitaxel is a potential treatment for cancer patients with bone metastases; the agents have…
Read morePoster: Drug/Disease Modelling - Oncology
A library of tumor growth and tumor growth inhibition models for the MonolixSuite
Thursday 16 October, 2025
Objectives: Time-course modelling of tumour growth (TG) and tumour growth inhibition (TGI) using ordinary differential equations (ODEs) has gained much traction…
Read moreModelling tumour growth and progression free survival of breast cancer patients treated with neoadjuvant therapy
Thursday 16 October, 2025
Background: Breast cancer (BC) is the most commonly diagnosed malignancy in the US and European women, with 23% (231,840) of new…
Read moreInfluence of the number of tumor size measurements on model-derived tumor size metrics and prediction of survival
Thursday 16 October, 2025
Objectives: The tumor size ratio (TSR), time-to-tumor growth (TTG) and tumor growth rate (KG) are frequently suggested predictors of overall…
Read moreAccuracy in the estimation of the hazard in simultaneous and sequential estimation approaches of tumor size and overall survival (OS) modeling
Thursday 16 October, 2025
Objectives: Frequently suggested tumor metrics of predicting overall survival (OS) in different tumor types are tumor-size time course (TSt), tumor…
Read moreA combined population kinetic-pharmacodynamic-overall survival model for docetaxel and paclitaxel in the treatment of HER2–negative metastatic breast cancer patients
Thursday 16 October, 2025
Introduction: Population modelling is increasingly used for describing tumor responses to anticancer treatments and different model-derived tumor metrics have been suggested…
Read morePopulation Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Thursday 16 October, 2025
Objectives: Daratumumab, a human IgG monoclonal antibody targeting CD38, has been approved to treat patients with multiple myeloma (MM). We…
Read morePopulation-based Target-Mediated Drug Disposition (TMDD) Pharmacokinetics Model of Daratumumab in Patients With Multiple Myeloma Following Intravenously Daratumumab Monotherapy
Thursday 16 October, 2025
Objectives: Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, has been developed and approved by FDA and EMA for…
Read moreImpact of interaction model choice in PKPD analysis evaluating drug combination in TGI in vivo studies
Thursday 16 October, 2025
Objectives: Combining drugs has become a usual strategy in oncology to improve treatment efficacy and/or reduce dose-related safety issue yet…
Read morePharmacokinetic time-dependency and covariates modelling of Isatuximab monoclonal antibody in multiple myeloma patients: analysis from pooled phase I/II & phase III studies
Thursday 16 October, 2025
Introduction Multiple Myeloma (MM) is a malignant disease characterized by clonal proliferation of plasma cells in the bone marrow and…
Read more